Skip to Content

Voxelotor Dosage

Medically reviewed by Last updated on Jan 8, 2020.

Applies to the following strengths: 500 mg

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Sickle Cell Anemia

1500 mg orally once a day

-This drug may be given with or without hydroxyurea.

Use: For the treatment of sickle cell disease.

Usual Pediatric Dose for Sickle Cell Anemia

12 years or older: 1500 mg orally once a day

-This drug may be given with or without hydroxyurea.

Use: For the treatment of sickle cell disease in patients 12 years or older.

Renal Dose Adjustments

Mild to severe renal impairment (CrCl 15 mL/min or greater): No adjustment recommended
ESRD: Data not available

Liver Dose Adjustments

Mild or moderate hepatic impairment: No adjustment recommended
Severe hepatic impairment: 1000 mg orally once a day

Dose Adjustments

Avoid concomitant use of strong or moderate CYP450 3A4 inducers, strong CYP450 3A4 inhibitors, or fluconazole; if use is unavoidable, adjust dose of voxelotor as follows:
-For use with Strong CYP450 3A4 Inhibitors or Fluconazole: Voxelotor 1000 mg orally once a day
-For use with Strong or Moderate CYP450 3A4 Inducers: Voxelotor 2500 mg orally once a day


-History of serious hypersensitivity reaction to the active substance or any product excipients; clinical manifestations may include generalized rash, urticaria, mild shortness of breath, mild facial swelling, and eosinophilia

Safety and efficacy have not been established in patients younger than 12 years.

Consult WARNINGS section for additional precautions.


Data not available

Other Comments

Administration advice:
-Take orally once a day with or without food
-Swallow tablets whole; do not cut, crush, or chew

Missed dose: If a dose is missed, skip missed dose and continue dosing on the following day

Storage requirements:
-Store below 30 C (86F)

-This drug is approved under the accelerated approval based on increase in hemoglobin (Hb); continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.

Patient advice:
-Patients should be instructed to read the US FDA-approved patient labeling (Patient Information).
-Patients should be instructed to immediately report signs or symptoms of hypersensitivity reactions such as generalized rash, urticaria, shortness of breath, facial swelling and eosinophilia.
-Patient should be instructed not to breastfeed and to speak with their healthcare provided if they are pregnant or planning to become pregnant.
-Patients should be instructed to tell their healthcare provider about all the medications they are taking including over-the-counter and herbal products.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.